Frontage Holdings Corporation has completed a major investment in expanding its pharmaceutical development and manufacturing capabilities. The company’s new GMP facility, operational since October 2025, features advanced commercial-scale equipment, including automated aseptic filling machines for vials, syringes, and cartridges, as well as specialized isolators, a tablet press, roller compactor, and Xcelodose system. The facility supports both clinical and small-scale commercial production of sterile, oral solid, and liquid dosage forms, with dedicated suites for high potency and non-sterile products. This expansion enhances Frontage’s ability to offer efficient, high-quality manufacturing solutions, particularly for small and mid-sized pharmaceutical companies seeking rapid clinical trials and market entry.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Frontage Holdings Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NE63520) on January 15, 2026, and is solely responsible for the information contained therein.